ライフサイエンスコーパス: NASBA

1 NASBA could be completed in 6.5 h versus 9 h for the Arg

2 NASBA offers several advantages, such as isothermal ampl

3 NASBA provided a standardized tool for the detection of

4 NASBA worked fairly well to quantitate HIV-1 RNA from al

5 NASBA-ECL and NASBA-beacon were similar in sensitivity,

6 e as follows: AMPLICOR MONITOR, 100 and 73%; NASBA HIV-1 QT, 84 and 100%; NucliSens HIV-1 QT, 99 and

7 ally, each standard was used separately in a NASBA reaction; subsequently, two internal standards wer

8 y nucleic acid sequence-based amplification (NASBA) (NucliSens Basic kit; BioMerieux), reverse transc

9 g nucleic acid sequence-based amplification (NASBA) and electrochemiluminescence (ECL) analysis.

10 f nucleic acid sequence-based amplification (NASBA) and quantitative real-time reverse transcription

11 y nucleic acid sequence-based amplification (NASBA) as markers of CMV infection.

12 e nucleic acid sequence-based amplification (NASBA) assay (bioMerieux, Durham, NC) were used to deter

13 A nucleic acid sequence-based amplification (NASBA) assay for qualitative detection of human cytomega

14 e nucleic acid sequence-based amplification (NASBA) assay that incorporates molecular beacon technolo

15 e Nucleic Acid Sequence-Based Amplification (NASBA) assay to determine the relationship with neurolog

16 l nucleic acid sequence-based amplification (NASBA) assay was optimized to amplify viral RNA of all f

17 f nucleic acid sequence-based amplification (NASBA) assays for the detection of West Nile (WN) and St

18 e nucleic acid sequence-based amplification (NASBA) detection and quantification platform for rapid d

19 g nucleic acid sequence-based amplification (NASBA) from Escherichia coli, Bacillus anthracis, and Cr

20 e-nucleic acid sequence-based amplification (NASBA) in an improved non-crosslinking mode for nanodiag

21 e nucleic acid sequence-based amplification (NASBA) method was investigated by use of an inhalational

22 g nucleic acid sequence-based amplification (NASBA) methodology as described previously.

23 e nucleic acid sequence-based amplification (NASBA) reaction with two exogenous internal standards fo

24 l nucleic acid sequence based amplification (NASBA) reaction.

25 Nucleic acid sequence-based amplification (NASBA) reactions have been demonstrated to successfully

26 A nucleic acid sequence-based amplification (NASBA) technique was used to quantify HIV-1 RNA as an in

27 l nucleic acid sequence-based amplification (NASBA) technique with which small amounts of virus RNA a

28 e nucleic acid sequence-based amplification (NASBA) using molecular beacon technology (NASBA-beacon)

29 g nucleic acid sequence based amplification (NASBA) with subsequent electrochemiluminescent detection

30 g nucleic acid sequence-based amplification (NASBA), an isothermal, primer-dependent technique.

31 , nucleic acid sequence-based amplification (NASBA), and loop-mediated isothermal amplification (LAMP

32 d nucleic acid sequence-based amplification (NASBA), have enabled detection, identification and quant

33 d nucleic acid sequence-based amplification (NASBA), standard reverse transcription PCR (RT-PCR), and

34 l nucleic acid sequence based amplification (NASBA), the assay was able to detect amplicons of 16S rR

35 h nucleic acid sequence based amplification (NASBA), this assay can detect concentrations of HIV RNA

36 e Nucleic Acid Sequence-Based Amplification (NASBA).

37 f nucleic acid sequence-based amplification (NASBA).

38 y nucleic-acid-sequence-based amplification (NASBA).

39 a nucleic acid sequence-based amplification (NASBA-QT) assay or the NucliSens assay.

40 NASBA-ECL and NASBA-beacon were similar in sensitivity, detecting 55 (

41 first proof of successful mRNA isolation and NASBA-based amplification of mRNA within a simple microf

42 it, and QIAGEN Ultra HIV extraction kit, and NASBA manual HIV-1 quantitative NucliSens.

43 Both RT-PCR and NASBA assays were efficient in detection of hMPV infecti

44 fected individuals were tested by RT-PCR and NASBA, 73 and 27% of CSF samples and 60 and 40% of breas

45 available kits (AMPLICOR MONITOR [Roche] and NASBA HIV-1 QT or NucliSens HIV-1 QT [Organon Teknika])

46 ce-based amplification and molecular beacon (NASBA-MB) detection system in multiplex format was devel

47 Both NASBA and qPCR showed a progressive increase in lung tis

48 Both NASBA assays were significantly more sensitive than cult

49 ere tested, and 44 were positive, 34 by both NASBA and RT-PCR and 5 each by NASBA or RT-PCR only.

50 heat shock, extraction, and amplification by NASBA were successfully detected and clearly distinguish

51 CMV late gene expression determined by NASBA was an accurate and early marker of CMV infection.

52 e, 34 by both NASBA and RT-PCR and 5 each by NASBA or RT-PCR only.

53 omes part of the final amplicon generated by NASBA.

54 CMV-NASBA was performed and results compared with serology,

55 Finally, a competitive NASBA reaction between one internal standard and the wil

56 he sequences were created in two consecutive NASBA reactions using the E. coli clpB mRNA sequence as

57 ivity and specificity, suggesting the duplex NASBA assay may be useful for rapid determination of agr

58 capture probe and electrochemiluminescence (NASBA-ECL assay) and a real-time assay with 6-carboxyflu

59 rocedure, including nucleic acid extraction, NASBA, and ECL detection.

60 ed from 0.1 pg and 10 pg total RNA taken for NASBA, respectively, in less than 2 h, producing a signa

61 The mRNA serving as the template for NASBA is produced by viable C. parvum as a response to h

62 nt rental were more expensive than those for NASBA-ECL; however, time to result was shortened by 1.5

63 controls consisting of previously generated NASBA amplicons could be diluted 10(15) fold and still r

64 esting strategy, using a barcoded isothermal NASBA reaction.

65 We present INSIGHT [isothermal NASBA (nucleic acid sequence-based amplification) sequen

66 othermal amplification (e.g. RPA, HDA, LAMP, NASBA, RCA, ICAN, SMART, SDA).

67 ic acid sequence-based amplification method (NASBA) and Roche's Amplicor HIV-1 Monitor (reverse trans

68 hese studies indicate that the CMV pp67 mRNA NASBA assay has reproducible and sensitive performance c

69 was also carried out regarding the design of NASBA primer pairs and detection probes, as well as reac

70 amplification demonstrate the usefulness of NASBA, standard RT-PCR, and TaqMan assays, in both resea

71 without the need for molecular, e.g., PCR or NASBA, amplification.

72 without the need for molecular, e.g., PCR or NASBA, amplification.

73 ion of the target, for example, using PCR or NASBA.

74 similar to the one already found for RT-PCR, NASBA, and RT-LAMP assays.

75 Positive NASBA assay results were obtained earlier than AG-IFA or

76 eled virus-specific molecular beacon probes (NASBA-beacon assay).

77 ng electrochemiluminescently labeled probes (NASBA-ECL) for detection of enteroviruses (EV) in 133 ce

78 A Q-NASBA-oriented sample preparation cassette is originally

79 nucleic acid sequence-based amplification (Q-NASBA) microfluidic platform composed of a membrane-base

80 ple preparation cassette, and a 24-channel Q-NASBA chip for environmental investigations on aquatic m

81 is developed for simple but robust on-chip Q-NASBA assays.

82 quentially, the extract is analyzed within Q-NASBA chips that are compatible with common microplate r

83 w-up (microscopy, 1.2% vs 8.9% [P < .05]; QT-NASBA, 36.7% vs 63.3% [P < .001]).

84 t baseline was 3.6% (microscopy) and 97% (QT-NASBA).

85 ucleic acid sequence-based amplification (QT-NASBA) are increasingly used to estimate pathogen densit

86 ucleic acid sequence-based amplification (QT-NASBA).

87 f Plasmodium falciparum gametocytaemia by QT-NASBA.

88 designed previously using a novel and rapid NASBA-based method.

89 Of 42 enterovirus-positive samples, NASBA detected 39 (92.9%) and RT-PCR detected 37 (88.1%)

90 For all whole-blood specimens, NASBA identified Aspergillus-positive samples in the gro

91 logy (NASBA-beacon) was compared to standard NASBA with postamplification hybridization using electro

92 n (NASBA) using molecular beacon technology (NASBA-beacon) was compared to standard NASBA with postam

93 hanced-sensitivity bDNA, and Organon Teknika NASBA HIV-1 QT) and two in-house assays (from National G

94 The NASBA and quantitative real-time RT-PCR assays demonstra

95 The NASBA and quantitative real-time RT-PCR assays detect LA

96 The NASBA assay can be used reliably to determine HIV RNA le

97 The NASBA assay detected clinically relevant recombinant vir

98 The NASBA assay had a lower limit of detection of 100 copies

99 The NASBA assay had a specificity of 100% based on the negat

100 The NASBA assay involved the use of silica to extract viral

101 The NASBA assay was able to detect dengue viral RNA in the c

102 The NASBA assays demonstrated exceptional sensitivities and

103 The NASBA primers as well as the ECL probes were highly spec

104 The NASBA-gold nanoprobe method was improved to lower the ov

105 The overall agreement between the NASBA assay and current reference tests was 86% when act

106 nce in estimated RNA copy number between the NASBA-QT assay and the AMPLICOR HIV-1 MONITOR test for i

107 e C6/36 assay, 66 were found positive by the NASBA assay, for a sensitivity of 98.5%.

108 m CMV-negative patients were negative by the NASBA assay, while 90% (10 of 11) of patient specimens t

109 cell culture or AG-IFA were positive by the NASBA assay.

110 ive) clinical specimens were positive by the NASBA assay.

111 During the NASBA reaction, a generic sequence is attached to all RN

112 e AMPLICOR HIV-1 MONITOR test and either the NASBA-QT assay or the NucliSens assay.

113 que detection formats were developed for the NASBA assays: a postamplification detection step with a

114 aving to separate the amplified RNA from the NASBA mixture.

115 es sandwich hybridization by hybridizing the NASBA-generated amplicon between capture probes and repo

116 ntially detecting any virus by modifying the NASBA protocol.

117 observed with CSF or CVL, nor in any of the NASBA assays.

118 the standard AMPLICOR test (12 of 19) or the NASBA assay (10 of 25).

119 ucleic acid extraction and purification, the NASBA reaction, amplification, and detection probes.

120 y nucleic acid amplification technology (the NASBA HIV-1 RNA QT system) was investigated.

121 These results indicate that the NASBA assay is a promising assay for the early diagnosis

122 region) at the 5'-end, which is added to the NASBA process.

123 human plasma spiked with dengue viruses, the NASBA assay had a detection threshold of 1 to 10 PFU/ml.

124 a HIV-1 RNA levels were quantitated with the NASBA HIV-1 RNA QT System from blood specimens that were

125 TaqMan assays, and standard RT-PCR, with the NASBA-beacon assay yielding results in less than 1 h.

126 The sensitivities and specificities of these NASBA assays were compared to those of a newly described

127 The analytical sensitivity of the real-time NASBA assay was <1 CFU/assay.

128 Real-time NASBA is highly sensitive and useful for the detection o

129 Real-time NASBA-beacon reagents and equipment rental were more exp

130 The multiplex real-time NASBA-MB assay provides a valuable platform for the rapi

131 ue to the unique synthesis process using two NASBA reactions rather than traditional cloning techniqu

132 in a surrogate organism and amplified using NASBA.

133 acted, purified, and finally amplified using NASBA.

134 A similar analysis using NASBA with paired blood plasma and CVL, saliva, or semin

135 This new rapid construction method via NASBA provides advantages over the traditional technique

136 r prepared panels (n = 24) was compared with NASBA HIV-1 RNA QT (an earlier version of NucliSens HIV-

137 amplified in a water bath for 60-90 min with NASBA, an isothermal technique that specifically amplifi